Maxime Teisseyre
YOU?
Author Swipe
View article: The personalized approach to rituximab treatment in membranous nephropathy: a multi-center randomized controlled trial
The personalized approach to rituximab treatment in membranous nephropathy: a multi-center randomized controlled trial Open
View article: Anticorps anti-rituximab dans les maladies auto-immunes et les hémopathies malignes : mise au point
Anticorps anti-rituximab dans les maladies auto-immunes et les hémopathies malignes : mise au point Open
Rituximab, a chimeric monoclonal antibody targeting the CD20, is a key therapy for treating haematological malignancies and numerous autoimmune diseases. However, its use may be complicated by the occurrence of anti-drug antibodies (ADA), …
View article: Rituximab counteracts loss of tolerance in membranous nephropathy patients through NK-mediated Treg induction
Rituximab counteracts loss of tolerance in membranous nephropathy patients through NK-mediated Treg induction Open
Background Membranous nephropathy (MN) is a chronic, autoimmune kidney disease characterized by an autoimmune response against podocyte-specific antigens, compromising renal functions. Few studies attempted to mechanistically describe how …
View article: #1928 Anti-drug antibodies are common in membranous nephropathy and affect response to rituximab: a multicenter study
#1928 Anti-drug antibodies are common in membranous nephropathy and affect response to rituximab: a multicenter study Open
Background and Aims Primary membranous nephropathy (pMN) is an autoimmune glomerular disease characterized by immune system dysregulation leading to podocyte damage through auto-antibodies and complement activation. According to KDIGO guid…
View article: Anti-Rituximab Antibodies Occurrence and Clinical Outcomes in Patients With Primary Membranous Nephropathy
Anti-Rituximab Antibodies Occurrence and Clinical Outcomes in Patients With Primary Membranous Nephropathy Open
View article: Artificial intelligence to guide rituximab therapy in patients with phospholipase A2 receptor–associated membranous nephropathy
Artificial intelligence to guide rituximab therapy in patients with phospholipase A2 receptor–associated membranous nephropathy Open
International audience
View article: Artificial intelligence-based personalised rituximab treatment protocol in membranous nephropathy (iRITUX): protocol for a multicentre randomised control trial
Artificial intelligence-based personalised rituximab treatment protocol in membranous nephropathy (iRITUX): protocol for a multicentre randomised control trial Open
Introduction Membranous nephropathy is an autoimmune kidney disease and the most common cause of nephrotic syndrome in non-diabetic Caucasian adults. Rituximab is now recommended as first-line therapy for membranous nephropathy. However, K…
View article: Treatment of nephrotic syndrome with anti-CD20 therapies in pregnancy: a case series and review of the literature
Treatment of nephrotic syndrome with anti-CD20 therapies in pregnancy: a case series and review of the literature Open
Membranous nephropathy (MN), focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD) are autoimmune kidney diseases and the most common causes of nephrotic syndrome. Anti-CD20 monoclonal antibodies are now recommended as…
View article: Obinutuzumab and Ofatumumab are More Effective Than Rituximab in the Treatment of Membranous Nephropathy Patients With Anti-Rituximab Antibodies
Obinutuzumab and Ofatumumab are More Effective Than Rituximab in the Treatment of Membranous Nephropathy Patients With Anti-Rituximab Antibodies Open
Obinutuzumab and ofatumumab are more effective than rituximab in treating patients with membranous nephropathy with anti-rituximab antibodies. Anti-rituximab antibodies should be systematically monitored, to determine appropriate treatment.
View article: Anti Phospholipase A2 Receptor 1 Antibodies and Membranous Nephropathy Recurrence After Kidney Transplantation
Anti Phospholipase A2 Receptor 1 Antibodies and Membranous Nephropathy Recurrence After Kidney Transplantation Open
View article: Corrigendum to “Analysis and Management of Rituximab Resistance in PLA2R1-Associated Membranous Nephropathy” [Kidney International Reports Volume 6, Issue 4, April 2021, Pages 1183-1188]
Corrigendum to “Analysis and Management of Rituximab Resistance in PLA2R1-Associated Membranous Nephropathy” [Kidney International Reports Volume 6, Issue 4, April 2021, Pages 1183-1188] Open
View article: #992 Protocol based on PLA2R1 epitope recognition is superior to standard protocol in achieving remission in PLA2R1-associated membranous nephropathy
#992 Protocol based on PLA2R1 epitope recognition is superior to standard protocol in achieving remission in PLA2R1-associated membranous nephropathy Open
Background and Aims Membranous nephropathy (MN) is a rare, but severe autoimmune disease affecting kidney glomeruli. Clinical evolution is variable, ranging from spontaneous remission to persistent nephrotic syndrome and kidney failure. Th…
View article: Optimization of Rituximab Therapy in Adult Patients With PLA2R1-Associated Membranous Nephropathy With Artificial Intelligence
Optimization of Rituximab Therapy in Adult Patients With PLA2R1-Associated Membranous Nephropathy With Artificial Intelligence Open
This algorithm could allow for early intensification of rituximab regimen in patients at high estimated risk of underdosing to increase the likelihood of remission.
View article: Both Humoral and Cellular Immune Responses to SARS-CoV-2 Are Essential to Prevent Infection: a Prospective Study in a Working Vaccinated Population from Southern France
Both Humoral and Cellular Immune Responses to SARS-CoV-2 Are Essential to Prevent Infection: a Prospective Study in a Working Vaccinated Population from Southern France Open
View article: Breakthrough infections due to SARS-CoV-2 Delta variant: relation to humoral and cellular vaccine responses
Breakthrough infections due to SARS-CoV-2 Delta variant: relation to humoral and cellular vaccine responses Open
Introduction COVID-19 vaccines are expected to provide effective protection. However, emerging strains can cause breakthrough infection in vaccinated individuals. The immune response of vaccinated individuals who have experienced breakthro…
View article: Risk Factors Associated with the Occurrence of Anti-rituximab Antibodies in Membranous Nephropathy
Risk Factors Associated with the Occurrence of Anti-rituximab Antibodies in Membranous Nephropathy Open
Teisseyre, Maxime; Brglez, Vesna; Cremoni, Marion; Fernandez, Céline; Graça, Daisy; Boyer-Suavet, Sonia; Benzaken, Sylvia; Esnault, Vincent L.M.; Seitz-Polski, Barbara Author Information
View article: Both humoral and cellular immune responses to SARS-CoV-2 are essential to prevent infection: a prospective study in a working vaccinated population from southern France
Both humoral and cellular immune responses to SARS-CoV-2 are essential to prevent infection: a prospective study in a working vaccinated population from southern France Open
COVID-19 vaccines have significantly decreased the number severe cases of the disease but the virus circulation remains important and questions about the need of new vaccination campaigns remain unanswered. The individual’s protection agai…
View article: Humoral and cellular responses after a third dose of SARS-CoV-2 mRNA vaccine in patients with glomerular disease
Humoral and cellular responses after a third dose of SARS-CoV-2 mRNA vaccine in patients with glomerular disease Open
View article: Toxic Occupational Exposures and Membranous Nephropathy
Toxic Occupational Exposures and Membranous Nephropathy Open
Background and objectives Membranous nephropathy is a rare autoimmune kidney disease whose increasing prevalence in industrialized countries pleads for the involvement of an environmental factor in the development of the disease. In additi…
View article: C5b-9 Glomerular Deposits Are Associated With Poor Renal Survival in Membranous Nephropathy
C5b-9 Glomerular Deposits Are Associated With Poor Renal Survival in Membranous Nephropathy Open
INTRODUCTION: Membranous nephropathy (MN) is the first cause of nephrotic syndrome in patients without diabetes. Its prognosis is variable, and treatment remains controversial because of potential toxicity. Currently, there is no reliable …
View article: Low baseline IFN-γ response could predict hospitalization in COVID-19 patients
Low baseline IFN-γ response could predict hospitalization in COVID-19 patients Open
The SARS-CoV-2 infection has spread rapidly around the world causing millions of deaths. Several treatments can reduce mortality and hospitalization. However, their efficacy depends on the choice of the molecule and the precise timing of i…
View article: Advances in the Management of Primary Membranous Nephropathy and Rituximab-Refractory Membranous Nephropathy
Advances in the Management of Primary Membranous Nephropathy and Rituximab-Refractory Membranous Nephropathy Open
Primary membranous nephropathy (pMN) is an auto-immune disease characterized by auto-antibodies targeting podocyte antigens resulting in activation of complement and damage to the glomerular basement membrane. pMN is the most common cause …
View article: Both Humoral and Cellular Immune Responses to SARS-CoV-2 are Essential to Prevent Infection: A Prospective Study in a Working Vaccinated Population from Southern France
Both Humoral and Cellular Immune Responses to SARS-CoV-2 are Essential to Prevent Infection: A Prospective Study in a Working Vaccinated Population from Southern France Open
View article: Low IFN-γ Response after Cell Stimulation Predicts Hospitalization in COVID-19 Patients
Low IFN-γ Response after Cell Stimulation Predicts Hospitalization in COVID-19 Patients Open
View article: Rituximab Immunomonitoring Predicts Remission in Membranous Nephropathy
Rituximab Immunomonitoring Predicts Remission in Membranous Nephropathy Open
Primary membranous nephropathy (pMN) is an autoimmune kidney disease and a common cause of nephrotic syndrome in adults. Rituximab is becoming a first line therapy for patients with persistent nephrotic syndrome with proven safety and effi…
View article: Contactin-1 is a novel target antigen in membranous nephropathy associated with chronic inflammatory demyelinating polyneuropathy
Contactin-1 is a novel target antigen in membranous nephropathy associated with chronic inflammatory demyelinating polyneuropathy Open
View article: Late diagnosis of chronic hypocalcemia due to autoimmune hypoparathyroidism
Late diagnosis of chronic hypocalcemia due to autoimmune hypoparathyroidism Open
Hypoparathyroidism is most often the result of postsurgical damage to the parathyroid glands but may occasionally be autoimmune hypoparathyroidism. In the latter context, activating antibodies directed against the calcium‐sensing receptor …
View article: Analysis and Management of Rituximab Resistance in PLA2R1-Associated Membranous Nephropathy
Analysis and Management of Rituximab Resistance in PLA2R1-Associated Membranous Nephropathy Open
Primary membranous nephropathy (pMN) is an autoimmune disease affecting kidney glomerulus and the most common cause of nephrotic syndrome (NS) in white adults without diabetes. The pathophysiology of pMN involves antibodies targeting podoc…
View article: Primary antiphospholipid syndrome associated with anti-phospholipase A2 receptor antibody-positive membranous nephropathy
Primary antiphospholipid syndrome associated with anti-phospholipase A2 receptor antibody-positive membranous nephropathy Open
Background The kidney is a major target in primary antiphospholipid syndrome. Several types of nephropathy have been reported, the most frequent being acute or chronic specific vascular nephropathies and membranous nephropathy. Case presen…